DDInter1835 DDInter927
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Topotecan {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Topotecan {u} (Compound) binds {v} (Gene) TOP1
Topotecan {u} (Compound) upregulates {v} (Gene) ALDH5A1
Topotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topotecan {u} (Compound) downregulates {v} (Gene) CCNF
Topotecan {u} (Compound) causes {v} (Side Effect) Mucosal inflammation
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Topotecan (Compound) treats peripheral nervous system neoplasm (Disease)
Topotecan (Compound) binds TOP1 (Gene)
Topotecan (Compound) upregulates ALDH5A1 (Gene)
Topotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Topotecan (Compound) downregulates CCNF (Gene)
Topotecan (Compound) causes Mucosal inflammation (Side Effect)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Topotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel